SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize ...
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. ESK-001, a tyrosine kinase 2 inhibitor, may be a ...
The actress, activist and wellness advocate teams with the renowned skin-care brand ESK to design a unique formula for sensitive, mature and reactive skin. By Erin Lassner E-Commerce Writer If you ...
Alumis Inc. has announced the successful completion of patient enrollment in its pivotal Phase 3 ONWARD clinical program for ESK-001, a treatment for moderate-to-severe plaque psoriasis, involving ...
Alumis announced positive Phase 2 OLE results for ESK-001, a TYK2 inhibitor for moderate-to-severe plaque psoriasis, showing sustained clinical improvements. Alumis Inc. has announced positive 52-week ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Alumis Inc., a precision immunology company that is reimagining the discovery, development and treatment of autoimmune disorders, today announced that the ...
Selma Blair may be best known for starring in classics like Cruel Intentions and Legally Blonde, but she’s recently added another impressive gig to her résumé. The actress just teamed up with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback